Alerts will be sent to your verified email
Verify Email
CHECKPOINT
|
Rubra Medicaments
|
South Asian Enter
|
Dalmia Indl. Dev
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-2.03 % | -14.71 % | 0.36 % |
|
5yr Avg Net Profit Margin
|
-0.31 % | -19.89 % | 1.15 % |
|
Price to Book
|
30.47 | 4.38 | 0.82 |
|
P/E
|
191.57 | 0.0 | 117.64 |
|
5yr Avg Cash Conversion Cycle
|
183.71 Days | -101.06 Days | -2913.44 Days |
|
5yr Average Interest Coverage Ratio
|
-248.31 | -36.96 | 219.1 |
|
5yr Avg ROCE
|
-2.28 % | -14.81 % | 0.51 % |
|
5yr Avg Operating Profit Margin
|
-0.3 % | -33.19 % | -2.87 % |
|
5 yr average Debt to Equity
|
0.06 | 0.33 | 0.03 |
|
5yr CAGR Net Profit
|
0.0 | 51.23 % | -22.16 % |
|
5yr Average Return on Assets
|
-1.63 % | -9.16 % | 0.31 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
0.0 | 61.07 % | 0.2 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Rubra Medicaments
|
South Asian Enter
|
Dalmia Indl. Dev
|
|---|